1 ified 771 incident cases of breast cancer during follow-up (
median time:
5.2 years).
2 Median time between first and reinfection swab was 64.5 days
3 The
median time between prior therapy and trial enrollment was 9
4 Median time between successful contacts was 3.0 (IQR, 3.0-3.7
5 The
median time between vitreoretinal surgery and orbital emphyse
6 cipients of cellular therapy (Allo, 35; Auto, 37; CAR T, 5;
median time from cellular therapy, 782 days; IQR, 354-1611 da
7 Median time from diagnosis to enrollment was 23 months (inter
8 The cohort included 163 patients with
median time from discharge to last recorded follow-up of 30 d
9 eatedly for up to 6 years (median three samples per person,
median time from first to last sample, 4.3 years).
10 The
median time from last active IBD episode to immunotherapy ini
11 al load at baseline was 7.90 (SD 1.82) Log10 copies/mL, and
median time from symptom onset to randomization was 3 days.
12 The
median time from the last injection to the time when cabotegr
13 Median time from transplant was 5.58 y (interquartile range 2
14 The
median time from transplantation to diagnosis was 10.5 years
15 The
median time interval between the two paired assessments was 1
16 us 60% in 2019; P<0.001), were overall shorter in duration (
median time of 11 minutes [8.5-26.5] versus 15 minutes [7.0-2
17 including a total of 270 patients presenting an ACS after a
median time of 12 (interquartile range, 5-17) months post-TAV
18 s (10.6%) required repeat intervention for IOP control with
median time of 3.17 years (IQR, 0.92-6.56) from first surgery
19 ack the quantity (number of items per 3 months) and timing (
median time of day) of purchases, and participant surveys pro
20 The
median time of hypotension per patient was 8.0 minutes (IQR,
21 The
median time of relapse after the most recent infusion was 2.6
22 Participants'
median time on ART prior to ATI was 3 years, and ATI lasted a
23 Median time on study was 36 weeks (range, 1-120 weeks).
24 The
median time since polycythaemia vera diagnosis was 8.2 years
25 The
median time to alleviation of symptoms was 79.0 hours for the
26 After recognition of HCM-LVSD, the
median time to composite outcome was 8.4 years.
27 ants and 1.15 per 1000 textured implants (1 in 871), with a
median time to diagnosis of 10.3 years (range, 6.4-15.5 yrs).
28 resulted in superior outcomes compared to melphalan alone (
median time to event 40.0 vs 25.0 days, respectively, p = 0.0
29 The
median time to first PrEP discontinuation was 159 days.
30 Median time to functional recovery was 7 and 9 days in the in
31 Median time to HCV RNA detection was dependent on HCV RNA lev
32 Median time to hematological response was 1 week.
33 Kaplan-Meier curves were constructed to examine
median time to HPV clearance overall, and by selected risk fa
34 Median time to IRIS was 11 days (interquartile range 7-40 day
35 OS from LT was 12.5 years, with a
median time to LT of 7.5 months [interquartile range, 4.4-10.
36 Median time to LT was 12.8 months in long wait regions, 6.5 m
37 Median time to lung cancer diagnosis in patients with (n = 29
38 at the time of testing; 24 subsequently developed symptoms (
median time to onset, 4 days).
39 Secondary outcomes were similar in both groups and include
median time to oral antibiotic stepdown, LOS, all-cause morta
40 Median time to pain progression was not estimable (NE; 95% CI
41 The
median time to parasitemia was significantly shorter in the s
42 Median time to radiological progression was 6 months (95% con
43 tor for better recurrence-free survival (P < 0.001), with a
median time to recurrence of 41.2 versus 5.5 months in nonres
44 Median time to response was 3.9 months (IQR 1.9-7.4).
45 Median time to return of spontaneous circulation was 21.1 min
46 Median time to surgery was 11 hours (IQR 4-40).
47 The
median time to surgical explant was 212 days, whereas 8.8% an
48 In the full analysis set,
median time to the first relapse was longer in the tocilizuma
49 The
median time to the next exacerbation was 32.5 days (interquar
50 Median times to neutrophil and platelet engraftment were comp